6 Further Research
6.1 Further good quality studies are needed:
to confirm the survival benefits, and the impact on QoL of gemcitabine as a first line treatment in comparison to commonly used 5-FU regimens.
to identify the value of gemcitabine as a second line treatment in pancreatic cancer.
to assess the cost-effectiveness of gemcitabine as a first and second line treatment in the light of any significant new effectiveness evidence.